
ãã³ãã³ã³ããªãç®æããªãããã¹ãéåïŒçš®é¡ãšãã®çç±ããŽãŒã«èšå®ã調æ»ãªã©
å¥åº·å¯¿åœã䌞ã°ãããã®éåãšã¯ãçµè«ããæžããšã幎霢ãšå ±ã«è¡°ããŠãæ®æ®µã®éåç¿æ £ã§ãã®è¡°ããé ãã§ãããé²ãããã«éåãããããšããããšã ããã®ãããªéåã¯äžã®3ã€ã ã
æé žçŽ éå
çåãã¬ãŒãã³ã°
æè»æ§ãäžããã¹ãã¬ãã
幎霢ãšãšãã«è¡°ããéåæ©èœã玹ä»ããããã«ç®æãã¹ããŽãŒã«ãå ãšãªã£ãŠããèãæ¹ãã©ããªçš®é¡ã®éåãã©ããããããã®ããªã©åããç¯å²ã§ç޹ä»ãããåŠãã ãã¿å ã䜵ããŠç޹ä»ãããã§ãããåŠã³ããæ¹ã¯ãã¡ããèŠãŠã¿ããšããçè§£ãæ·±ãŸããšæãã
1. ç®æãã¹ããŽãŒã«
äžèšã§èšããšãã³ãã³ã³ããªã ã
å¥ã®æžãæ¹ããããšãå¥åº·å¯¿åœãïŒã寿åœããç®æããšããããš
ãããããã³ãã³ã³ããªãç®æããããšèšã£ãŠãæŽé£²æŽé£ããŠå¥œãæŸé¡ãããšããããšã§ã¯ãªããããã€ã¡ãŒãžãã人ãããã¿ãããªã®ã§ã念ã®çºã«æžããŠããã
ããå
·äœçã«æžããšäººçã®æåŸã®10幎éãä»ãšåãããã«ç掻ãã§ããç¶æ
ã«ããããã«ãæ©ããã¡ããæºåãããŠãããšããããšã ã

2. å ã«ãªã£ãŠããèãæ¹ã¯Dr. Peter Attirã®Medicine 3.0
é·å¯¿ã«ã€ããŠã®å°éå®¶ã§å»åž«ã®Dr. Peter Attirã®èæžãOutliveã(è±èª)ã§Medicine 3.0ãšããèãæ¹ã玹ä»ããŠãããç°¡åã«ç޹ä»ããŠã¿ãã詳ããç¥ãããæ¹ã¯ãã²ããOutliveããèªãã§ã¿ãŠãã
Medicine 1.0: çŸä»£ã®è¥¿æŽå»çã®åã§ç ã¯æªéã«ãã£ãŠããããªã©ãšèããããŠãããšãã®èãæ¹
Medicine 2.0: çŸä»£ã®è¥¿æŽå»çã®ããšã ãç æ°ãçºçããã察åŠãããšèãæ¹ãçŸåšå»çã®çºå±ã§äººéã®å¯¿åœã¯é£èºçã«äŒžã³ã
Medicine 3.0: ç æ°ãçºçããåã«äºé²ãæ©æçºèŠãããŠå¥åº·å¯¿åœã䌞ã°ãèãæ¹
å³ã«ãããšäžã ã

Medicine 2.0ã¯ç æ°ã®çç¶ãåºãŠãã察åŠãã
äœãããªãç¶æ
ãšæ¯ã¹ãŠMedicine 2.0ã¯çæŽ»ç¿æ
£ç
ãçãªã©ãçºçãããšãã«è¬ãæ²»çãªã©ã§å¯ŸåŠãããŠãå€å°å¯¿åœã䌞ã°ããŠãããMedicine 2.0ã®ç¹ç·ã®å³äžã«ã³ãã®ããã«å¯¿åœã䌞ã³ãŠããã®ã¯ãæè¡ãããŠå»¶åœãããããšãæå³ããŠããã
寿åœã¯äŒžã³ããã®ã®ãå¥åº·å¯¿åœãã©ãã©ãäžãã£ãŠããã®ã§ããå¯¿åœ ïŒ å¥åº·å¯¿åœããšãªã£ãŠããã
Medicine 3.0ã¯äºé²ããåãçµãã§ãã
Medicine 3.0ã¯æ¥æ¬ã®æ»å ã®Top3ã§56ïŒ ã®ã·ã§ã¢ãç· ãããæªæ§æ°çç©ïŒçãèè «ïŒ30.1%ãå¿çŸæ£ïŒå¿èã«èµ·ããç æ°ïŒ15.8%ãè³è¡ç®¡çŸæ£ïŒè³çްèãç Žå£ãããç æ°ïŒ10.7%ã®çºçãé ãããããŸãã¯èµ·ãããªãããæ©æçºèŠããããã®è¡åãããŠãããšããããšã ã
æ»å ã®Top3ã§56%ã®ç æ°ãã¡ã¯ãã£ããç§ãã¡ã殺ããŠãã
ãã£ãããªæ»ã¯çºçãããŸã§ã«äœå¹Žãããã£ãŠçºçãããã®ã ã
æ¥æ¬ã§ã®æ»å ã®ã©ã³ãã³ã°ã«èŠããšããã5ãšã·ã§ã¢ãèŠãŠã¿ãããããïŒã§ã·ã§ã¢ã®56ïŒ
ãå ããŠããããããŠããããã®3ã€ã¯æ®æ®µã®çæŽ»ç¿æ
£ãã身äœã®äžã§ç©ã¿äžãã£ãŠçŸããŠãããšèããŠãããçã«é¢ããŠã¯ãŸã ã¡ãããšè§£æãããŠããªãã
æ¥æ¬ã§ã®æ»å ã®ã©ã³ãã³ã° - Top3ã§56%ã®ã·ã§ã¢ãå ãã
æªæ§æ°çç©ïŒçãèè «ïŒ30.1%
å¿çŸæ£ïŒå¿èã«èµ·ããç æ°ïŒ15.8%
è³è¡ç®¡çŸæ£ïŒè³çްèãç Žå£ãããç æ°ïŒ10.7%
èºç 9.8%
èè¡° 3.4%

å¥åº·å¯¿åœã䌞ã°ãã«ã¯çæŽ»ç¿æ £ç ã®çºçãé ããçºçããªãã»ãããã
çæŽ»ç¿æ
£ç
ã®çºçã®åå ã§ç§ãã¡ãã³ã³ãããŒã«ã§ããªãã®ã¯å 霢ã ã
ã§ããçæŽ»ç¿æ
£ã§äœã®äžéšãè¥è¿ãããããå éœ¢ãæ¢ããããå 霢ãé
ãããããšãã§ããã
éåžžã®äººã¯72æ³ãŸã§ã«ãªãããã®çãçºèŠãããããããšæ¯ã¹ãŠ100æ³ä»¥äžçããŠãã人ãã¡ã®5人ã«1人ãçãçºèŠããã幎霢ã100æ³ãšçŽ30幎éã®éããããã
å¿èçºäœãšè³åäžã代衚çãªå¿è¡ç®¡çŸæ£ã«é¢ããŠã25ïŒ ã®äººã75æ³ãŸã§ã«å¿è¡ç®¡çŸæ£ãšèšºæãããã100æ³ä»¥äžçããŠãã人ãã¡ã¯25ïŒ ã®äººãã¡ãåæ§ã«èšºæããã幎霢ã¯92æ³ãšããããŸã倧ããªéããããã
å¥åº·å¯¿åœã䌞ã°ãã®ãªãçæŽ»ç¿æ £ç ã®çºçãã§ããã ãé ãããããšãè³¢æã ãšæã£ãŠããã ããã®ã§ã¯ãªãã ããã
å¥åº·å¯¿åœã䌞ã°ãããã«ç§ãã¡ãã³ã³ãããŒã«ã§ããã«ããŽãªãŒã¯4ã€
çæŽ»ç¿æ £ã®äžã§å¥åº·ã«å€§ãã圱é¿ãããã®ãäžã®4ã€ã
éå
é£ç掻
ç¡ç
ã¹ãã¬ã¹
Dr. Gabrielle Lyonã®Podcastã§Sexual Healthã«ã€ããŠã®æš©åšã®Dr. Mo Kheraãã²ã¹ãã«è¿ããŠPodcastã§ãDr. Mo Kheraãç¹°ãè¿ã話ããã®ããæ£è ããã«ãŸãããããããããšãè¬ã飲ãããšã§ãªããäžã®4ã€ã®çæŽ»ç¿æ £ãæ¹åããããšã ããã®ãšããœãŒãã§ã¯EDãæ£ã£ãŠããç·æ§ã«å¯ŸããŠãçæŽ»ç¿æ £ã®æ¹åãææ¡ãããšè©±ããŠããããããŠEDãæ£ããšããããšã¯å¿è¡ç®¡çŸæ£ã®åæçç¶ã ãšã話ããŠããã
éåãäžçªå¹æçãªè¬ã ïŒ
éåã¯å¥åº·å¯¿åœã䌞ã°ãäžã§äžçªå¹æãããããã以äžã®ãã®ã¯ãªã
æªãç¥ããã¯è¬ãšæ¯ã¹ãŠæéãšåŽåãããã
å¥åº·å¯¿åœã䌞ã°ãããã«ã©ã®ãµããªãããã®ããªã©æ©ãæéãããã®ãªãããã®æéãéåã«æè³ããçèãçåãã€ãããã¬ãŒãã³ã°ãæé
žçŽ éåãããããšã倧äºãšPeter Attiaãå£ãé
žã£ã±ãããŠèšãç¶ããŠããã圌以å€ã«ã®å»åž«ãåæ§ã®ããšãèšã£ãŠããããšãèããããšãããã
å¥åº·å¯¿åœãé·å¯¿ãå°éãšããPeter Attiaå»åž«ã¯éåãäžã®ããã«ã«ããŽãªãŒåãããŠããã
ã¹ã¿ããªãã£ãŒïŒå®å®æ§ïŒ
ã¹ã¿ããªãã£ãŒã¯ãã©ã³ã¹ãšæè»æ§ã®2ã€ã®èŠçŽ ã®å ãšãªã
çåãã¬ãŒãã³ã°
æå€§é žçŽ æåé(Vo2Max)ãéãã
äœè² è·ïŒZone 2ïŒã®æé žçŽ éå
é«è² è·ïŒZone 5ïŒã®éå
ãããã®èœåãäžèšã§èšããšã幎霢ãšå ±ã«è¡°ããŠããäœã®æ©èœã§ã³ã³ãããŒã«ã§ãããã®ãã ãã§ã¯ãããã«è©³ãã玹ä»ããŠãããŸãã
幎霢ãšå ±ã«è¡°ããŠããäœã®æ©èœã§ã³ã³ãããŒã«ã§ãããã®
ããã§ã¯äžã®3ã€ã®èŠãŠã¿ãããŸã ããã©ã³ã¹ã¯åèªèº«ãå匷äžè¶³ãªã®ã§ãããã§æžãããšã¯çç¥ãã
æå€§é žçŽ æåé
åŒåžãããŠäœå ã«é žçŽ ãåãå ¥ããäºé žåççŽ ãäœã®å€ã«åºãããšãè¡ããæå€§é žçŽ æåéã¯1åéã«äœé1kgãããåã蟌ãããšãã§ããé žçŽ ã®éïŒml/kg/åïŒãæããŠãããã
çå
çåã¯å€ãã®äººãåãããšããçèããçºæ®ã§ããåã®ããšã ã人çã®æåŸã®10幎ã§ä»ã®åæ§ã®ç掻ãããããšæãã®ã§ããã°ãä»ããéããããšã匷ãããããã§ããã
æè»æ§
çåãæå€§éã«çºæ®ããããã«ã¯åºãå¯ååã§èº«äœãåããããšãéèŠã§ãããæè»æ§ãäžãã£ãããéæ®µãç»ãããšããããè¶³ãæãããã«äžãããªããŠã€ãŸãããšããããšãæªãã·ããªãªãšããŠèããããã
èŠãKPIãšç®æããŽãŒã«ã®äœãæ¹
Vo2MaxïŒæå€§é žçŽ æåéïŒ
æå€§é žçŽ æåéã¯äžã®å¹Žéœ¢ãšãšãã«äžãã£ãŠããã瀺ããŠããã

ãŽãŒã«èšå®ãããåã«ç®æããšãããèãã
人çã®æåŸã®10幎éãäŸãã°90æ³ãŸã§çããã€ãããªãã80æ³ãã90æ³ã®éã§äœãã§ãããªç¶æ ã§ãããã®ããå ·äœçã«æ³åããŠã¿ããåã®å Žåã¯äžã®4ã€ã ããã
è·ç©ãæã£ãŠå£ãããšã¹ã«ã¬ãŒããç»ãéãã§ãã
å®¶æïŒå«ãã²å«ïŒãšå±±ããã€ãã³ã°ãããŠå€§èªç¶ãäžç·ã«æ¥œãã¿ãã
åŠ»ãšæ¥ã æ£æ©ãããŠäººçã«ã€ããŠè©±ãåãç¶ããã
劻ãšã¿ã³ãŽãèžãç¶ããã
決ããŠé«æã¿ãããŠããããã§ã¯ãªãã ãããåãšäžã§æžããããšã«èªåãã§ããããã«ãªããããšæã人ã¯å€ãã®ã§ã¯ãªãã ãããã
掻åå 容ããšã«å¿ èŠãªVo2MaxïŒæå€§é žçŽ æåéïŒ
èªåã®ããããããšãšäœæ³ãŸã§çãããã®ããåããã°ãäžã®Peter Attiaå»åž«ã玹ä»ããã°ã©ããéåžžã«åãããããã
äžã®ã°ã©ãã¯å€§ãã2ã€ã®ããšãäŒããŠãã
幎霢ãšå ±ã«Vo2Maxã¯äžãã£ãŠãã
掻åå 容ããšã«å¿ èŠãªVo2Maxãåãã

äŸãã°ãåã¯90æ³ã®ãšãã«äžã®åçã®ããã«ãå®¶æïŒå«ãã²å«ïŒãšå±±ããã€ãã³ã°ãããŠå€§èªç¶ãäžç·ã«æ¥œãã¿ãããããã«å¿ èŠãªVo2Maxã¯ã10°ã®åã5km/hã§æ©ããã®ã¬ãã«ã ãããVo2Max 25ãå¿ èŠã«ãªããã°ã©ãã¯å¹Žéœ¢ã75æ³ãŸã§ãããªãããç·è²ã®é«ããã£ãããã¹ã®ãšãªãŒãã°ã«ãŒãã«ããã°90æ³ã§Vo2Maxã25ãããã«ãªãããšãäºæ³ã§ããã

Vo2MaxïŒæå€§é žçŽ æåéïŒç®æãã¹ããŽãŒã«
ã©ããã£ãŠã幎霢ãšãšãã«Vo2Maxã¯äžããã®ã§ãä»ã®ãã¡ã«é«ãããŠããããšããä»ã§ããæåã®ããšã«ãªããããã§ããã°ç®æãã¹ãVo2Maxã¯èªåã®å¹Žéœ¢ããã20æ³è¥ã幎霢ã®Elite(ãšãªãŒã)ã®å€ã ã
äžã®è¡šã¯å¹Žéœ¢å¥ã®Vo2Maxã®è¡šãèŠãŠç®æãã¹ãå€ã決ãŸãããã
åã¯ä»52æ³ã ããã32æ³ã®Eliteã¯53以äžã«ãªããã ããVo2Maxã53以äžã«ããã®ãç®æšãšãªãã
ä»ïŒ2024幎7æïŒã®èªåã®Vo2Maxã¯51.9
Vo2Maxã¯ããŸããŸãªæ¹æ³ã§èšæž¬ã§ããããã£ãšãæ£ç¢ºãªæ°å€ãç¥ãããã®ãªãã©ãã§äžã®ããã«ãã¹ã¯ãããŠèšæž¬ãããšæ£ç¢ºãªVo2Max ãåŸãããã
ãšããããšã§7æ3æ¥ã«æ£ç¢ºãªVo2Maxãèšæž¬ããã

ã©ãã«è¡ã£ãŠæ£ç¢ºã«Vo2Maxãèšæž¬ãããšããããªæ°å€ãèšæž¬ããŠããã
èèªãšã°ã«ã³ãŒã¹ãççŒãããéåã®åŒ·åºŠ
軜ãã©ã³ãã³ã°ã®ãšãã¯èèªãççŒããã
éå匷床ãäžãããšèº«äœãèèªããã°ã«ã³ãŒã¹ãçæãšããŠãã
èªåã«ãšã£ãŠã®æé žçŽ éåã®åŒ·åºŠã®å¿ææ°ã®ç¯å²ãæ£ç¢ºã«åãã
äžã®ãã£ãŒããšè¡šã¯åã®ãã¹ãçµæãšåã®åŒ·åºŠå¥ã®æé žçŽ éåã®èæã®ç¯å²ãæããŠãããŠãã

Vo2Maxããã簡䟿ã«èšæž¬ããããšãã§ãã
ã©ãã«è¡ã£ãŠVo2Maxãã¹ãããããªããŠããããŸããŸãªæ¹æ³ã§Vo2Maxãèšæž¬ã§ãããæ£ç¢ºãã«ã¯ããããã©ããApple WatchãGarminã®è
æèšãªã©ãVo2Maxãæšå®ããŠãããã
äŸãã°ãåã¯æèŒªåã®ãã©ããã³ã°ããã€ã¹OURARINGãæè¿ãVo2Maxãèšæž¬ããããã«ãªã£ãã
OURARINGã§äœåãVo2Maxãèšæž¬ããçµæã¯46ãã54ã ã£ããã¡ããã©ã®éãã©ãã«è¡ã£ãŠèšæž¬ããVo2MaxãšäžèŽããã®ã§ãæ®æ®µã¯OURARINGã§Vo2MaxãèŠãŠããã°ãããšããããšãåãã£ãã

ãã®ä»ããã©ããã³ã°ããã€ã¹ã䜿ããªãã§ãVo2Maxãèšæž¬ã§ããã®ã§ãèå³ãã人ã¯èª¿ã¹ããšããŸããŸãªæ¹æ³ãåºãŠããŸãã
Vo2Maxã®ããäžã€ã®ãã£ã¬ã³ãž
ããã¯æ°åéã³ã¿ãããªãšãããããããäžã®ãããªãã£ã¬ã³ãžãã§ããã
äœæ³ãŸã§èªåã®Vo2Maxã®å€ãä»ã®å¹Žéœ¢ãäžåãããšãã§ããã ãã
äžã®å¹Žéœ¢å¥Vo2MaxãèŠããšãç·æ§ã¯40代ã女æ§ã¯30代ã§Above AverageïŒå¹³å以äžïŒã®Vo2Maxã®å€ãšå¹Žéœ¢ã亀差ããã幎霢ãVo2Maxãäžåããšããããšã ã
Vo2MaxããšãªãŒãã«ããŽãªãŒã«åŒãäžãããš50代ã§Vo2Maxãšå¹Žéœ¢ã亀差ãããŸã§é ãããããšãã§ããã
åã¯52æ³ã§Vo2Maxã51.9ãªã®ã§ããªããšããã®ãã£ã¬ã³ãžããŸã ã§ããã
çå
çåã¯Vo2Maxã»ã©åèªèº«ã®åŠã³ããªãã®ã§ãåããç¯å²ã§æžããŠã¿ãŸãã
ãŽãŒã«èšå®ãããåã«ç®æããšãããèãã
ç®æãã¹ãçåã人çã®æåŸã®10幎éã§ãäœãã§ããããã§ããããããããèããŠã¿ããåã¯äžã®ããšãã§ããããã§ããã
éç«ã¡ãä»ã®ããã«ã§ãã
é£è¡æ©ã®æ£ã«è·ç©ãä¹ãããã
å«ãã²å«ã«æ±ã£ãããã ããããšãã«æ±ã£ãããã
å«ãã²å«ã«é«ãé«ããããŠãããã
劻ãšãšã¬ã楜ãã¿ãã
1çªã¯æ®éã®äººããèŠããšãããããšæãã ãããã2çªãã4çªã¯èª°ããã§ããããã«ãªã£ãŠãããã®ã§ã¯ãªãã ãããïŒ
ãããã®ããšãã§ããã«ã¯ãä»ã®æ®µéã§äžã®ããšãã§ããçåãå¿
èŠã ãšèããããšãã§ããã
èªåã®äœéãããããªããã§ãã
ããããã³ã°ã1åéã2幎éã§ãã
ç©ºæ°æ€ åã2åéã§ãã
åã¯ããã¯ããŸãå³å¯ã«å®çŸ©ããŠããªããåžžã«ã¯ã©ã€ãã³ã°ãéç«ã¡ãèªéãã¬ãŒãã³ã°ã§çåãéããŠãã身äœã®ããã©ãŒãã³ã¹ãåäžãããŠããã
å°ãªããŠãäžã®ããšã¯äœè£ã§ã§ããç¶æ
ã§ããã®ãšãããªãçåã®ããã©ãŒãã³ã¹ã¯é«ããšèªè² ããŠããã
ãã£ãšè©³ããåãã£ãŠãããããããæžãè¶³ããŠãããŸããã
æè»æ§
æè»æ§ã¯ç¹ã«ç·æ§ããèŠããšè»œèŠããã¡ãªéåã«ããŽãªãŒã§ã¯ãªãã ãããïŒåèªèº«ãããã ã£ããé«éœ¢ã«ãªã£ãŠæè»æ§ãæžå°ããŠå¯ååãå°ãããªã£ãŠãããšãä»ãŸã§è¶³ãäžããŠç»ãããšãã§ããæ®µå·®ãå°é£ã«ãªãã±ãŒã¹ãèŠåããããã¿ããã ãã ããæè»æ§ã軜èŠã¯æ±ºããŠã§ããªãã
ãŸã ãåèªèº«ãé«éœ¢ã«ãªã£ããšãã®ç®æãã¹ãæè»æ§ã«ã€ããŠã¡ãããšæç€ºããã®ãèŠããŠããªã®ã§ã詳ããåãã£ãã远èšããŸãã
Vo2MaxïŒæå€§é žçŽ æåéïŒãšå¯¿åœã«é¢ãã調æ»ã玹ä»
é¢çœã調æ»ãDr. Peter Attirã玹ä»ããŠããããããããã§æ¥æ¬èªã§ç޹ä»ãããçµè«ã¯ãã£ãããã¹ã¬ãã«ïŒVo2MaxïŒæå€§é žçŽ æåéïŒã®é«ããšå¯¿åœãéçžé¢ãããšèšãããšã ãèšãæãããšæå€§é žçŽ æåéã®å€ãé«ããšé·ãçããå¯èœæ§ãé«ããšããããšã
調æ»å 容
12.2äžäººã察象ãšãã調æ»
å¹³å幎霢ã¯53æ³
å šå¡ãVo2MaxïŒæå€§é žçŽ æåéïŒã®ãã¹ããè¡ããçµæã«åºã¥ããŠåé¡
ã«ããŽãªãŒã®åé¡
Low:äžçªäœãã«ããŽãªãŒã¯å šäœã®äžäœ25ïŒ ãŸã§ã®äººãã¡
Below Average(å¹³å以äž): ã®äººãã¡ã¯å šäœã®äžãã25%ãã50ïŒ ã®éã®äººãã¡
Above Average: å šäœã®50ïŒ ãã75ïŒ ã«äœçœ®ãã人ãã¡
High: ã¯å šäœã®ããã75ïŒ ãã95ïŒ ã«äœçœ®ãã人ãã¡
Elite: ããã5ïŒ
Lowããbelow average, above average, highãšããããã®ã«ããŽãªãŒã§ã¯çŽ30,000人ã»ã©ã®äººãã¡ãåãŸã£ãŠãã
Eliteã°ã«ãŒãã«ã¯3,500人ãåãŸã£ã
NOTE: åã°ã«ãŒãã¯äººå£ãåæ ãããã®ã§ã¯ãªã
çµè«
å šæ»å æ»äº¡çãèŠããšãã£ãããã¹ã¬ãã«ïŒVo2Maxã®é¢ä¿ã¯æããã§Vo2Maxãäžãããšå šæ»å æ»äº¡çãäžãããã¬ã³ã
ãã£ãããã¹ã¬ãã«ïŒVo2MaxãäžçªäœãâLow"ã°ã«ãŒããä»ã°ã«ãŒããšæ¯ã¹ãŠå šæ»å æ»äº¡çïŒHazard rateïŒãå§åçã«é«ã


äžã®ã°ã©ããã«ããŽãªãŒå¥ã®é¢ä¿ãèŠãŠã¿ãã
Lowã°ã«ãŒãããæ¬¡ã®äžã®25ïŒ ã®Below AverageïŒå¹³å以äžïŒã°ã«ãŒãã«è¡ãã ãã§ã次ã®10幎éã§ã®å šæ»å æ»äº¡ç(HR)ãååã«ãªã
Lowã°ã«ãŒããã2ã€äžã®25ïŒ ã®Above AverageïŒå¹³å以äžïŒã°ã«ãŒãã«è¡ããšå šæ»å æ»äº¡ç(HR)ã®ãªã¹ã¯ã60%~70%æžã
ã°ã«ãŒãéã§ã®å šæ»å æ»äº¡çã®äžçªäœãæ¹åçã¯Highã°ã«ãŒãããEliteïŒãšãªãŒãïŒã°ã«ãŒãã§ããŸãæ¹åãããªãããçµ±èšçãªåªäœæ§ã¯ååã«ããéã
次ã«ã°ã«ãŒãã®äžã§å«ç ãç³å°¿ç ãªã©ãæã£ãŠãã人ãã¡ã®ãªã¹ã¯ã玹ä»ãã

äžã®ãã£ãŒãã®è峿·±ããšããã玹ä»ãã
äžã®è¡šã®Group Comparisonã¯ãããã«äžã§ç޹ä»ããã°ã©ããšåãããšãèšã£ãŠããã
Lowã«ããŽãªãŒãšElite(ãšãªãŒã)ã°ã«ãŒããæ¯èŒãããšæ¬¡ã®10幎éã§ã®å šæ»å æ»äº¡çã5åãéã
å šæ»å æ»äº¡çã«é¢ä¿ãããšæããã人ãã¡ãæãåºããŠãå šæ»å æ»äº¡çã«ã©ãé¢ä¿ããã®ãã調æ»ããŠãããäžã®èŠå ãã©ããããå šæ»å æ»äº¡çãé«ããã®ãã玹ä»ãã
å«ç : 41%
èè¡æ§å¿çŸæ£ïŒCADãå¿èã®çèãæ é€ããŠããè¡ç®¡ã§ããå åèã®è¡æµãäœäžããããšã§èµ·ããç æ°ïŒïŒ29%
ç³å°¿ç : 40%
é«è¡å§: 21%
æ«æè äžå š (è èã®åããäœäžããŠãæ£åžžã®è èã®10ïŒ ä»¥äžã®åãããã§ããªããªã£ãç¶æ ): 180%
ãã£ãããã¹ã¬ãã«ïŒVo2Max:æå€§é žçŽ æåéïŒã®æ¹åããããšã¯ãä»ã®æ»äº¡ã«é¢ä¿ãããšæãããããšæ¯èŒããŠãéåžžã«å€§ããªã€ã³ãã¯ããäœãããšãæ¯èŒããŠçè§£ããã ããã ãã
äŸãã°ãäžçªæ»äº¡ãªã¹ã¯ãé«ããæ«æè äžå šïŒ180ïŒ ã®ãªã¹ã¯å¢å ïŒãšãã£ãããã¹ã¬ãã«ãLowã«ããŽãªãŒããAbove Average:å¹³å以äžã«è¡ãã®ãšåããªã¹ã¯ã®åºŠåãã ã
Lowã«ããŽãªãŒããAbove Average ã«ããŽãªãŒã«Vo2Max:æå€§é žçŽ æåéãæ¹åããããšã¯å®çŸå¯èœãªããšã§ãã
ãŸãšãããš
ãã®èª¿æ»çµæãèŠããšããã£ãããã¹ã¬ãã«ïŒVo2Max:æå€§é žçŽ æåéïŒã®äžçªäœãã°ã«ãŒãã«ã¯ããããªããããããããšããããããããåªåããããšã§Below AverageïŒå¹³å以äžïŒã°ã«ãŒãã«è¡ãåªåãããããšã§10幎éã§ã®å šæ»å æ»äº¡ç(HR)ãååã§ããã
幎霢ãšãšãã«è¡°ããçåãçèãæ©ããã¡ããéãã
çåã¯äœãããªããšå¹Žã
10%ãã€èœã¡ãŠãããšèšãããŠãããäžã®è¡šã¯çèéãšçåã幎霢ãéããããšã«æžã£ãŠããããšã瀺ããŠãã調æ»çµæã ã
幎霢ãšãšãã«çèéãçåãäžãã£ãŠãããããŸãã¯çåãå
ã«èœã¡ãããšãããçèéã¯çåã«åœ±é¿ããã®ã§ãçèéãå¢ããããšã§èœã¡ãçåãè£ãããšãã§ãããšããããšããããã®ããŒã¿ããèªã¿åããã

çèéãçåã®ãã¬ãŒãã³ã°ãäœãããªããŸãŸãé«éœ¢ã«ãªã£ãŠçèãå°ãªããªããšãä»ãæ®æ®µã®ç掻ã§è¡ãªã£ãŠããæ¥åžžçæŽ»ãã§ããªããªããè·ç©ãæã€ãè²·ãç©ã«è¡ããå«ãæ±ã£ããããªã©ã®ããšã ã
å¥ã®è³ªåããããšäººçã®æåŸã®10幎éãã©ã®ããã«éããããèªåèªçããŠã¿ãããè»æ€ åã§éããããã®ããä»ã®åãããã«ç掻ããããã®ãã©ã¡ãããªïŒåŸè ãªãä»ããçåãéãç¶ããããšãéèŠã«ãªã£ãŠããã
äžã®ã°ã©ããäžã®è¡šãããèŠãããã®ã§è²Œãä»ããŠãããŸãã

æè»æ§ã幎霢ãšãšãã«äœäžãã
æè»æ§ãäžãããšé¢ç¯ã®å¯ååãçãŸããäŸãã°ãè¶³ãäžããããé«ããäœããªããšããããšã ãæè»æ§ãäžããããšã§ãä»ãŸã§ç»ããéæ®µãç»ãã«ãããªãããšãªã©ãèããããã ããããããã«ããçåãšå¯ååã¯å¯æ¥ãªé¢ä¿ã«ããããšã¯å®¹æã«çè§£ã§ããã ããã
Dr. Hubermanlab ã®æè»æ§ã«é¢ããPodcastã§20æ³ãã49æ³ã®éã§10幎ããšã«æè»æ§ã¯~10%ãã€æžã£ãŠãããšæããŠãããŠããã
äžã®ã°ã©ããã¹ããŒãåºã®å ±åæžã®äžã®ã°ã©ãã§ãå¹Žéœ¢ãšæè»æ§ã®é¢ä¿ã衚ããŠããã20æ³ãéãããšæè»æ§ã¯äžãã£ãŠããåŸåã«ããããšãèŠãŠãšããã

ã¹ãã¬ãããããã¡ãªãããšããŠã¯äžã®ããšãäžããŠããã
å¥åº·å šè¬ïŒãã©ã³ã¹ãã¹ã¿ããªãã£ãŒïŒã®æ¹å
å§¿å¢ã®æ¹å
æ©ãæ¹ã®æ¹å
身äœã®ããã©ãŒãã³ã¹ã®åäž
çã¿ã®æžå°
ççã®æžå°
é¢çœãããŒã¿ãšããŠã¯ãçã®è «çã®æé·ãã¹ãã¬ããã«ãã£ãŠé ããããšããããŠã¹ã䜿ã£ãå®éšããŒã¿ãããã
Vo2Maxãåäžãããããã®éå
Vo2MaxïŒæå€§é žçŽ æåéïŒãåäžãããããã®ã¢ãããŒãã¯ãããããããã人ããããã®éåã®ã¬ãã«ã«ãã£ãŠå€§ããå€ãã£ãŠããã
1ã€Dr. Peter Attiaã話ããŠããã®ã¯ãŸãŒã³2ã®æé
žçŽ éåãé±ã«3æé以äžããããŠããŸãŒã³2ã80%ã®éã ãšãããããŸãŒã³5ã®æå€§å¿ææ°ãã¬ãŒãã³ã°ãããã 20%ãããšè©±ããŠããã
ãŸãŒã³2ãšã¯æ©ãããããµã€ã¯ãªã³ã°ããªãããªããšãã話ãã§ãã軜ãåŒ·åºŠã®æé
žçŽ éåã ã

éåç¿æ £ãç¡ãæ¹ãªããä»®ã«é±ã«2åã®ïŒïŒåã®ãŠãªãŒãã³ã°ããå§ããŠéåç¿æ £ãç¯ããŠããããšããå§ããã®ãçŸå®çã ããã
人ããããã®éåã¬ãã«ãéãã®ã§ãèªåã«ãã£ãããã°ã©ã ã¯å°éãã¬ãŒããŒã«çžè«ããŠäœã£ãŠã¿ãŠãã ããã
åã¯Vo2Maxãåäžããããã«äœããŠããã
åã¯äžã®2ã€ã®æé žçŽ éåãããŠãããããã§é±ã«3æé以äžã«ãªã£ãŠããã
é±3åã®ã¯ã©ã€ãã³ã°ãžã ã§ã¯ã©ã€ãã³ã°ãããŠãããšãã®æåŸã®30åã§ç°¡åãªã¯ã©ã€ãã³ã°èª²é¡ã30åãã³ã¹ãããã§ç»ã£ãŠãã
å¹³æ¥ãã¯ã©ã€ãã³ã°ã«è¡ã£ãŠããªããŠå®¶ã§ä»äºããŠããæ¥ãšé±æ«ã«äžå¥³ãæŒå¯ããŠãããšãã«30åã©ã³ãã³ã°ããŠããã
äŒç€Ÿã®éå€ã§ã®ãŠãªãŒãã³ã°ãçé20åãåŸåŸ©ã§40åãé±ã«1ã3å
çåãéããããã®éå
ã©ã®ããã«ããŠçåãéããã®ãã¯æ¬åœã«äººããããã ã
åèªèº«ã¯èªåèªèº«ã楜ããããšãè¡ãªãããšãããããã«ããŠãããããããããšã§ç¶ãã®ãšã楜ãããã粟ç¥çã«ãè¯ãã
åã¯çååäžã®ããã«äœããŠããã
å
šèº«ã®çå
å
šèº«ã®çåã¯ã¯ã©ã€ãã³ã°ãã¯ãããšããéåã§æ¥œããéãç¶ããŠãã
äžå身ã®çå
äžå身ã®çåã¯éç«ã¡ãšèªéãã¬ãŒãã³ã°ã§éãç¶ããŠããããããŸã楜ããã§ããã
äžå身ã®çå
ã¯ã©ã€ãã³ã°ã§ã¯åŒ·ãäžåèº«ãæ±ããããã®ã§ãäžã®é«åºŠãªèªéã¹ã¯ã¯ãããã§ããããã«ãªã£ãã
æè»æ§ãäžããããã®ããã®ã¯ã¹ãã¬ãã
ã¹ãã¬ãããå§ããããšããæ¹ã«ãã€ãããããããŠããã®ãã15åã20åã§å
šèº«ã®ã¹ãã¬ãããã§ããã¡ãã¥ãŒããå§ããããšã ã
ãããªã¡ãã¥ãŒã¯YouTubeã«ãããããããäžã®YouTubeåç»ã¯15åã§å
šèº«ã®ã¹ãã¬ãããã§ããã¡ãã¥ãŒã ã
æåã«å€§äºãªããšã¯äžã®2ã€ã
ç¿æ £ã«ããããšã
ã¹ãã¬ããããã£ãããšæ°æã¡ãããšæããçšåºŠã«ããããš
ç¿æ £ã«ãªã£ãããã ãã ãèªåã®èå³ã®æ¹åã§åºããŠããã°ãããšæãããŸãã¯ãã¬ãŒããŒã«çžè«ããŠã¿ãŠãã
åã¯æè»æ§ãäžããããã«äœããŠããã
åã¯ä»ã¯é±ã«4æ¥éã»ã©1æéãã€ã¹ãã¬ãããããŠãããåãæè»æ§ãåäžããŠã©ããªã£ãã®ãã玹ä»ããŸãã
4å¹Žéæ¥ã ã1æéçšåºŠã®ã¹ãã¬ãããããŠå€ãã£ãããš
2019幎ããçé¢ç®ã«ã¹ãã¬ãããããããã«ãªãã2020幎ã®ã³ããã»ãã³ãããã¯ããã£ããã«æ¯æ¥40åã1æéã¹ãã¬ããããããã«ãªã£ãã
ãã®ããšã§æè»æ§ã¯åäžããã®ã¯åœããåãªã®ã ããããã«å ããŠãããŸããŸãªäœã®äžèª¿ãåçã«æžã£ããããã¯å人差ã人ããããã®çç¶ãããã®ã§ä»ã®äººã«åœãŠã¯ãŸããšã¯éããªããæè»æ§ãåäžãããçèãæãããä¿ã€ããšã¯èº«äœã®ã³ã³ãã£ã·ã§ã³ãæ¹åããããšã«å€§ããè²¢ç®ããããšãäœéšããããšãã§ããã
ã¹ãã¬ãããçé¢ç®ã«ããåã®ç¶æ

éŠãèª¿åæªãããæ¯æ1åã2åã¯ã«ã€ãã«è¡ã£ãŠç¯æ£ããŠããããªããšå¯ããªããªããããéŠãæ°æã¡æªããªã
æ¿ããéåããããšã¯è °ã®çèããã³ãã³ã«ç¡¬ããªããæã«ãã£ãŠã¯ç¿æ¥åããªããªãããšããã£ã
幎ã«ïŒã2åã¯è °ã®çèã硬ããªãçã¿ãæ©ããªããªããšãããã£ã
ã¹ãã¬ãããçé¢ç®ã«ããç¶ããä»ã®ç¶æ

éŠã¯èªåã§æ¥ã ã¹ãã¬ããããŠã¡ã³ããã³ã¹ãããŠããããã«ã€ãã«è¡ããªããŠãããªã£ã
éååŸã«è °ãçããªãããšãã»ãšãã©ãªããªã£ããããŸã«è °ã®çèã硬ããªã£ããšãã¯ãããµãŒãžã¬ã³ãšã¹ãã¬ããã§èªåã§çèãã»ãããŠãã
æ©ããªããªãã»ã©è °ã®çèãçããªãããšã2åãã£ããã2åç®ã¯3æ¥éèªåã§ã¹ãã¬ãããããŠæ²»ãã
èªåã®èº«äœãèªåã§ã¡ã³ããã³ã¹ããããã«ãªã£ã
身äœã®ãã¡ãã¡ãçããšããããšããªã
ã¹ãã¬ãããããŠå¯ååãåºãä¿ã¡ããŸãã¯ããåºãããããšã®ãããã£ããããããããã以å€ã®ãããã£ãããããã®ã§ãåã¯éèŠèŠããŠãã
æåŸã«
å¥åº·å¯¿åœã䌞ã°ãããã«ããã¹ãéåãé·ã
ãšæžããŠããŸã£ããå
šéšèªãã§ããã ããã®ãªãæ¬åœã«ããããšãã
äœãåèã«ãªãã°å¬ããããèªåã®éåç¿æ
£ãããã«ãããããã£ããã«ãªãã°ãããå¬ããã
èªåã®èº«äœã¯èªåã§ããããŠãããªããšèª°ãããããŠãããªãã®ã§ãèªåèªèº«ã§åªåããããšã決æããããšãããå§ãŸãã ãšæãã
ããªãã®çŽ æµãªå¥åº·å¯¿åœãæå€§åããããšãå¿ããç¥å¿µããŠããã